larotrectinib

This page shows the latest larotrectinib news and features for those working in and with pharma, biotech and healthcare.

FDA gives Loxo breakthrough tag for second cancer drug

Its pipeline is headed by larotrectinib which has a BTD for patients with locally advanced or metastatic solid tumours harbouring an NTRK gene fusion mutation and has already been submitted for ... Last year, Bayer paid an impressive $400m upfront with

Latest news

Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

Bayer and Loxo hopeful about novel biomarker-led cancer treatment. Loxo Oncology and Bayer should hear from the FDA about their tumour biomarker-targeted cancer drug larotrectinib by 26 November, after ... TRK inhibitor Larotrectinib is being reviewed by
Pharma sales help Bayer escape the worst from a bumpy 2017

But those failures were tempered by positive results late in the year for larotrectinib, one of two cancer assets licensed from Loxo Oncology in a $1.5bn deal. ... Larotrectinib is expected to be filed for US approval within the coming weeks, and the
Roche buys cancer company Ignyta for $1.7bn

That high level of response was behind Bayer’s decision to stump up $1.55bn to license Loxo’s larotrectinib, which is also in phase II basket trials involving patients with
Bayer gets clinical data to support $1.5bn Loxo deal

Bayer gets clinical data to support $1.5bn Loxo deal. Larotrectinib’s response rate likely to be practice changing. ... Larotrectinib’s near universal response rate and compelling durability of response in paediatric patients with TRK fusion cancers
Joerg Moeller to head Bayer R&D after operational shake-up

Among the highlights on the agenda are a look at its emerging cancer pipeline, including Loxo-sourced TRK inhibitors larotrectinib and LOXO-195 as well as projects in oncogenic signalling,

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Cancer immunotherapy: What's on the horizon?

also extending to targeted cancer drugs, with Loxo Oncology and Bayer’s larotrectinib filed for TRK gene fusion tumours and due for an FDA verdict in November.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Medical Writer - Creative and Scientific Projects: DOE

Healthcare PR Director: £100, 000 – £120, 000 benefits

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Medical Writer: Salary is DOE

Account Manager- 4 days per week or full-time: Salary TBC

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Associate Scientific Director: Salary TBC

Healthcare PR Senior Account Manager: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Graduate Scientific Editor: DOE

Systematic Review Lead- London: Negotiable

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Writer, Healthcare Advertising, London: Excellent package

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Sudler London - Senior Medical Writer: Competitive

Account Director, Healthcare Advertising Agency: Salary TBC

Senior Training Manager - Surrey: Competitive Salary &Bonus

Senior Account Manager – Healthcare Advertising: Salary TBC

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Subscribe to our email news alerts

PMHub

Add my company

CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....